drugset / Trial / NCT03109236
Autologous Endothelial Progenitor Cell Therapy for Reversal of Liver Cirrhosis
Phase 3
Unknown
66 enrolled
National University Hospital, Singapore
Changi General Hospital · collabSingapore General Hospital · collabTan Tock Seng Hospital · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This proposal translates a hypothesis driven basic research into clinical setting to determine the potential of using autologous CD133+ cells to reverse fibrosis and improve clinical outcome for patients with end stage cirrhosis. This has significant impact on the management of cirrhosis.
Timeline
- Start
- 2017-08-24
- Primary completion
- 2022-12-31
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | GCSF | Unknown | — | Subcutaneous |